Sparsentan Drug Interactions: Hypotension, Hyperkalemia, Renal Risk, CYP3A
Sparsentan(Filspari)is a dual endothelin-receptor+angiotensin II AT1-receptor antagonist used in chronic kidney disease such as primary IgA nephropathy.Because one molecule hits two pathways,interaction risk concentrates on four fronts:hypotension,hyperkalemia,acute kidney injury,and CYP3A exposure shift.
Contraindicated combinations
ARBs:irbesartan,valsartan,losartan,candesartan,telmisartan,olmesartan,etc.
Endothelin receptor antagonists(ERAs):bosentan,ambrisentan,macitentan.
Direct renin inhibitor:aliskiren.
These must be discontinued before starting sparsentan;triple RAAS blockade markedly raises hypotension,syncope,hyperkalemia,and acute renal failure risk.
Use with caution+close monitoring
ACE inhibitors(benazepril,lisinopril,enalapril):no direct combination data;dual RAAS blockade is theoretically risky—use only after specialist weighting,with intensified BP,K⁺,creatinine/eGFR checks.
Other antihypertensives(amlodipine and other CCBs,beta-blockers):additive BP lowering—dizziness and orthostatic hypotension;down-titrate the companion antihypertensive if needed.
Diuretics:thiazides/loops can cause volume depletion→hypotension and pre-renal creatinine rise;potassium-sparing diuretics(spironolactone,eplerenone,triamterene,amiloride)and finerenone mainly add hyperkalemiarisk and are generally not recommended.
NSAIDs(ibuprofen,naproxen,celecoxib and other COX-2 inhibitors):in volume-depleted or renally impaired patients they can precipitate acute kidney injury;not an absolute ban,but monitor for worsening renal function.
Metabolic interactions(CYP3A axis)
Sparsentan is primarily a CYP3A substrate.
Strong CYP3A inhibitors(itraconazole,clarithromycin,ritonavir/lopinavir,nefazodone,grapefruit juice):increase exposure—avoid;if unavoidable,interrupt sparsentan and re-titrate after the inhibitor stops.
Moderate CYP3A inhibitors(cyclosporine,fluconazole,nelfinavir,diltiazem):cautious couse—monitor BP,K⁺,edema,renal function.
Strong CYP3A inducers(rifampicin,carbamazepine,phenytoin,St.John’s wort):reduce exposure and efficacy—avoid;moderate inducers(efavirenz,dexamethasone,phenobarbital)need caution;prefer low-induction steroids(budesonide,prednisone).
Antacids:avoid within 2 hours before/after dosing;acid-reducing agents per local label.
Sparsentan weakly induces CYP2B6/2C9,moderately induces 2C19,and weakly inhibits P-gp/BCRP—check narrow-therapeutic-index substrates.
Potassium-raising agents—one red line
KCl,potassium supplements,potassium-based salt substitutes(low-sodium salt),trimethoprim,potassium-sparing diuretics—not recommended;if unavoidable,check K⁺frequently;K⁺>5.5 mmol/L warrants dose adjustment,interruption,or removing the companion drug.
Required monitoring
Blood pressure:sitting and standing—hypotension and orthostasis.
Renal:serum creatinine,eGFR,urine output.
Electrolytes:serum potassium is the priority;intensify with diuretics or renal impairment.
Liver:ALT,AST,total bilirubin before start;then ALT/AST monthly for 12 months,every 3 months thereafter;interrupt if ALT or AST>3×ULN.
Volume status:weight,ankle/leg edema,dyspnea(fluid retention).
Boxed warning
Hepatotoxicity:class effect includes transaminase elevation and liver failure;follow the REMS schedule.
Embryo-fetal toxicity:pregnancy contraindicated;effective contraception before,during,and for the label-specified period after therapy;stop immediately if pregnancy occurs.Breastfeeding not recommended.
Bottom line:sparsentan is not“one more antihypertensive”—it shuts RAAS and endothelin together.ARBs/ERAs/aliskiren are banned,ACEIs are caution-only,strong CYP3A both directions avoided,potassium-adders off the table;everything else rides on BP–K⁺–creatinine–LFT monitoring.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)